CEO: Clive Dix

Advent Contact: Raj Parekh

Needle-free DNA delivery device

PowderMed developed the Particle Mediated Epidermal Delivery (PMED) technology for needle-free delivery of DNA vaccines into the skin as a dry powder formulation of gold particles.

Advent invested in the Series A in 2004. PowderMed was acquired by Pfizer in 2006.

 

Pfizer buys British vaccine company PowderMed

Back